Traduction de «machine pour essais de fatigue » (Français → Anglais) :

The standard shall describe stability tests, performance tests to assess maximum loads, drive train, braking, steering, frame parts endurance and fatigue tests.

(Return tabled) Question No. 199 Ms. Kirsty Duncan: With regard to the development and operation of the Canadian Multiple Sclerosis Monitoring System (CMSMS) announced in March 2011: (a) what are the government's baseline assumptions for the CMSMS, (i) how many Canadians live with MS according to the government’s source, (ii) what is the government's source; (b) what have been the challenges in developing the system between March 2011 and today, (i) how has each challenge been overcome, (ii) what are the achievements to date, (iii) w ...[+++]hat milestones has the government planned between December 2013 and December 2015 and by what dates; (c) what is the cost of developing the system, broken down by costs to date; (d) how much money did the Canadian Institutes for Health Research (CIHR) contribute to the development of the CMSMS, (i) were there any other partners involved in the development of the system, (ii) if so, who are they, (iii) what has each contributed; (e) who was involved in the design and development of the CMSMS, (i) from what departments/institutions were they, (ii) were potential conflicts of interest declared and, if so, how; (f) what health information does the CMSMS track, specifically, with regard to (i) chronic cerebrospinal venous insufficiency (CCSVI), (ii) impacts of CCSVI treatment, including but not limited to use of the following scales, Expanded Disability Status Scale, Modified Fatigue Impact Scale, Multiple Sclerosis Impact Scale, and Multiple Sclerosis Quality of Life Inventory, (iii) pharmaceutical treatments for MS, (vi) adverse drug reactions by MS drug; (g) who is/was overseeing pilot testing, (i) who is/was responsible for ensuring that patient information is/was protected, (ii) who is/was responsible for the integrity of the results; (h) were ethical reviews for pilot testing necessary and, if so, on what date did each pilot site pass ethical review; (i) when is pilot testing expected to/did it take place and at which MS clinics ...

Question No. 53 Ms. Kirsty Duncan: With respect to the chronic cerebrospinal venous insufficiency (CCSVI) clinical trial being undertaken by Dr. Traboulse: (a) what milestones are reportable to the government, (i) on what date(s) is reporting expected to occur, (ii) how will this information be communicated to patients, the medical community, and the general public; (b) on what date did each of the trial sites pass ethical review; (c) on what date did recruitment of patients begin for each of the trial sites; (d) how many patients with multiple sclerosis (MS) are being recruited for each site, and how is consistency in diagnosis and t ...[+++]reatment being ensured across sites; (e) who is performing the diagnoses for CCSVI for each site, (i) how is the diagnosis being performed, including, but not limited to, ultrasound and venogram, (ii) how many diagnoses has each person undertaking the diagnosis at each site performed prior to the study, and by whom was each person trained; (f) who is performing the procedures for each site, (i) how is the procedure being performed, including, but not limited to, anesthetic, balloon size, (ii) how many procedures has each person undertaking the procedure at each site performed prior to the study, and by whom was each person trained; (g) what are the selection criteria for the trial, including, but not limited to, type of MS, Expanded Disability Status Scale (EDSS) score, venous abnormality/malformed valve/stenosis, mobility, (i) how do these criteria compare with the international literature, (ii) with how many international studies to date will the selection criteria be analytically comparable; (h) if both progressive and relapsing-remitting forms of MS are to be examined in the trial, how will statistical significance be ensured given that 50 of 100 patients will undergo a “sham” procedure, 25 patients will have a progressive form of the disease, and 25 will have a relapsing-remitting form of the disease, and will people with bo ...

3.2.1. The test machine shall have a rotary inertia simulating that part of the linear inertia of the vehicle mass acting upon one wheel, necessary for the cold performance and hot performance tests, and capable of being operated at constant speed for the purpose of the test described in points 3.5.2 and 3.5.3.

v1=initial speed (km/h) v2=final speed (km/h) Po=mass of the drawing vehicle (kg) under test conditions P1=mass of the trailer borne by the non-braked axle(s) (kg) P2=mass of the trailer borne by the braked axle (kg) 3.2.Inertia dynamometer tests 3.2.1.The test machine shall have a rotary inertia simulating that part of the linear inertia of the vehicle mass acting upon one wheel, necessary for the cold performance and residual performance tests, and capable of being operated at constant speed for the purpose of the test described in items 3.5.2 and 3.5.3 below.

Before placing a machine on the Market, the manufacturer, or his authorized representative established in the Community, in order to certify the conformity of machinery, shall draw up documentation comprising: A technical construction file composed of: - an overall drawing of the machinery together with the drawings of the control circuits; - full detailed drawings, accompagnied by any calculation notes, test results, etc. required to construct the machinery; - a description of the methods adopted to eliminate hazards presented by the machinery; - as well as technical reports or certificates obtained from a competent body, and - a cop ...[+++]y of the instruction handbook for the machinery.